- Home
- DSY vs IVVD Comparison
DSY vs IVVD Comparison
Compare DSY & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- IVVD
- Stock Information
- Founded
- DSY 2020
- IVVD 2020
- Country
- DSY China
- IVVD United States
- Employees
- DSY N/A
- IVVD N/A
- Industry
- DSY
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- IVVD Health Care
- Exchange
- DSY Nasdaq
- IVVD Nasdaq
- Market Cap
- DSY 58.8M
- IVVD 69.0M
- IPO Year
- DSY N/A
- IVVD 2021
- Fundamental
- Price
- DSY $1.25
- IVVD $0.94
- Analyst Decision
- DSY
- IVVD Strong Buy
- Analyst Count
- DSY 0
- IVVD 3
- Target Price
- DSY N/A
- IVVD $5.85
- AVG Volume (30 Days)
- DSY 45.4K
- IVVD 3.1M
- Earning Date
- DSY 02-10-2025
- IVVD 05-15-2025
- Dividend Yield
- DSY N/A
- IVVD N/A
- EPS Growth
- DSY 120.37
- IVVD N/A
- EPS
- DSY 0.01
- IVVD N/A
- Revenue
- DSY $7,323,356.00
- IVVD $36,688,000.00
- Revenue This Year
- DSY N/A
- IVVD $606.63
- Revenue Next Year
- DSY N/A
- IVVD $83.30
- P/E Ratio
- DSY $101.45
- IVVD N/A
- Revenue Growth
- DSY 16.37
- IVVD N/A
- 52 Week Low
- DSY $0.75
- IVVD $0.35
- 52 Week High
- DSY $6.98
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- DSY 38.53
- IVVD 64.44
- Support Level
- DSY $1.21
- IVVD $0.81
- Resistance Level
- DSY $1.51
- IVVD $0.94
- Average True Range (ATR)
- DSY 0.09
- IVVD 0.12
- MACD
- DSY -0.03
- IVVD 0.02
- Stochastic Oscillator
- DSY 0.02
- IVVD 65.86
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.